D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 78 Citations 22,082 494 World Ranking 10560 National Ranking 113

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Internal medicine
  • Breast cancer

Patrick Neven focuses on Breast cancer, Internal medicine, Oncology, Gynecology and Tamoxifen. His research on Breast cancer concerns the broader Cancer. His Internal medicine study combines topics from a wide range of disciplines, such as Placebo and Endocrinology.

His Oncology research is multidisciplinary, relying on both Adenocarcinoma, Endocrine system, Estrogen receptor and Pathology. He has included themes like Pregnancy, Cohort study, Anastrozole, Predictive value of tests and Proportional hazards model in his Gynecology study. His studies examine the connections between Tamoxifen and genetics, as well as such issues in Endometrium, with regards to Uterus, Hysteroscopy and DNA damage.

His most cited work include:

  • Association analysis identifies 65 new breast cancer risk loci (569 citations)
  • MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. (536 citations)
  • Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies (502 citations)

What are the main themes of his work throughout his whole career to date?

Patrick Neven spends much of his time researching Internal medicine, Breast cancer, Oncology, Cancer and Tamoxifen. Internal medicine is a component of his Estrogen receptor, Chemotherapy, Aromatase inhibitor, Letrozole and Metastatic breast cancer studies. In his research, Debulking and Ovarian cancer is intimately related to Surgery, which falls under the overarching field of Breast cancer.

His work is dedicated to discovering how Oncology, Exemestane are connected with Everolimus and other disciplines. His Cancer study combines topics in areas such as Placebo and Clinical endpoint. The concepts of his Tamoxifen study are interwoven with issues in Endometrium, Endocrinology, Aromatase and Prospective cohort study.

He most often published in these fields:

  • Internal medicine (64.58%)
  • Breast cancer (58.63%)
  • Oncology (52.83%)

What were the highlights of his more recent work (between 2019-2021)?

  • Internal medicine (64.58%)
  • Oncology (52.83%)
  • Breast cancer (58.63%)

In recent papers he was focusing on the following fields of study:

Patrick Neven mainly focuses on Internal medicine, Oncology, Breast cancer, Cancer and Metastatic breast cancer. In his study, Progressive disease is strongly linked to Gastroenterology, which falls under the umbrella field of Internal medicine. His research investigates the connection with Oncology and areas like Abemaciclib which intersect with concerns in Early breast cancer.

His research in Breast cancer is mostly concerned with Tamoxifen. His Cancer research incorporates themes from Biomarker and Estrogen. Patrick Neven has researched Metastatic breast cancer in several fields, including Cancer research, Trastuzumab and Phases of clinical research.

Between 2019 and 2021, his most popular works were:

  • Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with PIK3CA-mutated (mut) hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) + aromatase inhibitor (AI): BYLieve study results. (23 citations)
  • Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy. (16 citations)
  • Integrated Data Analysis of Six Clinical Studies Points Toward Model-Informed Precision Dosing of Tamoxifen (10 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Breast cancer

His scientific interests lie mostly in Internal medicine, Breast cancer, Oncology, Cancer and Fulvestrant. His study explores the link between Internal medicine and topics such as Gastroenterology that cross with problems in Progressive disease. Patrick Neven works in the field of Breast cancer, focusing on Estrogen receptor in particular.

The various areas that Patrick Neven examines in his Oncology study include Tamoxifen, Proportional hazards model, MSH2, CYP2D6 and MSH6. His work in Cancer addresses issues such as Biomarker, which are connected to fields such as Estrogen. His Fulvestrant study integrates concerns from other disciplines, such as Brief Pain Inventory, Aromatase inhibitor, Placebo and Hormone receptor.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Associations of Breast Cancer Risk Factors With Tumor Subtypes: A Pooled Analysis From the Breast Cancer Association Consortium Studies

Xiaohong R. Yang;Jenny Chang-Claude;Ellen L. Goode;Fergus J. Couch.
Journal of the National Cancer Institute (2011)

781 Citations

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.

George W. Sledge;Masakazu Toi;Patrick Neven;Joohyuk Sohn.
Journal of Clinical Oncology (2017)

747 Citations

Association analysis identifies 65 new breast cancer risk loci

Kyriaki Michailidou;Kyriaki Michailidou;Sara Lindström;Sara Lindström;Joe Dennis;Jonathan Beesley.
Nature (2017)

691 Citations

Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98

Giuseppe Viale;Meredith M. Regan;Eugenio Maiorano;Mauro G. Mastropasqua.
Journal of Clinical Oncology (2007)

510 Citations

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2

M. Piccart;G. N. Hortobagyi;M. Campone;K. I. Pritchard.
Annals of Oncology (2014)

464 Citations

Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche

John R.B. Perry;Felix Day;Cathy E. Elks;Patrick Sulem.
Nature (2014)

424 Citations

Genome-wide association studies identify four ER negative-specific breast cancer risk loci

Montserrat Garcia-Closas;Fergus J. Couch;Sara Lindstrom;Kyriaki Michailidou.
Nature Genetics (2013)

414 Citations

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

Giuseppe Viale;Anita Giobbie-Hurder;Meredith M. Regan;Alan S. Coates.
Journal of Clinical Oncology (2008)

396 Citations

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: MONALEESA-3

Dennis J. Slamon;Patrick Neven;Stephen Chia;Peter A. Fasching.
Journal of Clinical Oncology (2018)

394 Citations

Lasofoxifene in postmenopausal women with osteoporosis.

Steven R. Cummings;Kristine E Ensrud;Pierre D. Delmas;Andrea Z. LaCroix.
The New England Journal of Medicine (2010)

381 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Patrick Neven

Graham G. Giles

Graham G. Giles

University of Melbourne

Publications: 228

Roger L. Milne

Roger L. Milne

Cancer Council Victoria

Publications: 206

Jenny Chang-Claude

Jenny Chang-Claude

German Cancer Research Center

Publications: 149

Hiltrud Brauch

Hiltrud Brauch

German Cancer Research Center

Publications: 135

Melissa C. Southey

Melissa C. Southey

Cancer Council Victoria

Publications: 132

Douglas F. Easton

Douglas F. Easton

University of Cambridge

Publications: 131

Paul D.P. Pharoah

Paul D.P. Pharoah

University of Cambridge

Publications: 111

Frédéric Amant

Frédéric Amant

Antoni van Leeuwenhoek Hospital

Publications: 105

Matthias W. Beckmann

Matthias W. Beckmann

University of Erlangen-Nuremberg

Publications: 101

Christopher A. Haiman

Christopher A. Haiman

University of Southern California

Publications: 100

Wei Zheng

Wei Zheng

Vanderbilt University Medical Center

Publications: 100

Montserrat Garcia-Closas

Montserrat Garcia-Closas

National Institutes of Health

Publications: 98

John L. Hopper

John L. Hopper

University of Melbourne

Publications: 97

Per Hall

Per Hall

Karolinska Institute

Publications: 96

Peter Kraft

Peter Kraft

Harvard University

Publications: 94

Fergus J. Couch

Fergus J. Couch

Mayo Clinic

Publications: 90

Trending Scientists

Dragomir R. Radev

Dragomir R. Radev

Yale University

Bezalel Peleg

Bezalel Peleg

Hebrew University of Jerusalem

Pedro Barquinha

Pedro Barquinha

Universidade Nova de Lisboa

Melissa A. Denecke

Melissa A. Denecke

University of Manchester

Xiao-Qin Liu

Xiao-Qin Liu

Nanjing Tech University

Xiaoling Yang

Xiaoling Yang

East China University of Science and Technology

Haiguang Zhao

Haiguang Zhao

Qingdao University

Boris Lenhard

Boris Lenhard

Imperial College London

Richard P. Woychik

Richard P. Woychik

National Institutes of Health

Makoto Arita

Makoto Arita

RIKEN

Jon Nissen-Meyer

Jon Nissen-Meyer

University of Oslo

Chaozhe Zhu

Chaozhe Zhu

Beijing Normal University

Svein Magnussen

Svein Magnussen

University of Oslo

Antonio Verdejo-García

Antonio Verdejo-García

Monash University

Anthony H. Gonzalez

Anthony H. Gonzalez

University of Florida

Claus Leitherer

Claus Leitherer

Space Telescope Science Institute

Something went wrong. Please try again later.